TerminatedPhase 2

Open-lable Extension Study on Safety and Efficacy of Neramexane to Treat Congenital and Acquired Nystagmus

United Kingdom48 participantsStarted 2009-05

Plain-language summary

The purpose of this study is to investigate the long-term safety, tolerability and efficacy of neramexane mesylate in the treatment of congenital idiopathic nystagmus (CIN). In addition, a subgroup of multiple sclerosis (MS) patients suffering from acquired nystagmus will be included.

Who can participate

Age range18 Years – 81 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * patients who has succesfully completed the lead-in study MRZ 92579-0707/1 Exclusion Criteria: * Occurence of any major treatment-emergent adverse event or condition during the previous protocol (MRZ 92579-0707/1)

What they're measuring

Long-term safety, Visual acuity

Timeframe: Baseline, week 4, month 3, 6, 9, 12, 18, 24, 30, 36 and follow-up

Trial details

NCT IDNCT00799942

SponsorMerz Pharmaceuticals GmbH

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

View on ClinicalTrials.gov More Nystagmus, Congenital trials